Welcome to our dedicated page for Prothena news (Ticker: PRTA), a resource for investors and traders seeking the latest updates and insights on Prothena stock.
Prothena Corporation plc (NASDAQ: PRTA) is described in its own press releases as a late-stage clinical biotechnology company focused on protein dysregulation in neurodegenerative and rare peripheral amyloid diseases. The PRTA news feed on Stock Titan aggregates these company communications, giving investors and observers a single place to follow Prothena’s disclosures and milestones.
In its recent news, Prothena has highlighted progress across a pipeline that includes both wholly-owned and partnered programs. Updates have covered clinical development for Parkinson’s disease through the prasinezumab collaboration with Roche, ATTR amyloidosis with cardiomyopathy via coramitug (formerly PRX004) now being developed by Novo Nordisk, and Alzheimer’s disease programs such as BMS-986446 (formerly PRX005) with Bristol Myers Squibb, PRX012, and the dual Aβ/tau vaccine PRX123. The company has also issued releases on its CYTOPE technology platform, workforce restructuring, and financial results.
Readers of the PRTA news page can review press releases on topics such as Phase 2 and Phase 3 trial plans, Fast Track designations, preclinical data from the TDP-43 CYTOPE program, and corporate actions including an Extraordinary General Meeting to approve a capital reduction to create distributable reserves. Governance and leadership updates, such as changes to the Board of Directors, are also disclosed through these announcements.
By following this curated stream of Prothena’s own news, users can see how the company presents the status of its investigational therapeutics, collaborations with partners like Roche, Novo Nordisk and Bristol Myers Squibb, and its capital and cost structure decisions. The PRTA news page is intended as a convenient starting point for reviewing Prothena’s publicly released information over time.
Prothena Corporation (NASDAQ:PRTA) announced participation in upcoming investor conferences, highlighting its late-stage clinical biotechnology focus on protein dysregulation. Key events include:
- Citi’s 17th Annual BioPharma Conference on September 8, 1x1 investor meetings.
- Morgan Stanley 20th Annual Global Healthcare Conference on September 13, with a fireside chat at 5:15 PM ET.
- H.C. Wainwright 24th Annual Global Investment Conference on September 14, fireside chat at 9:00 AM ET.
- Cantor Neurology & Psychology Conference on October 6, 1x1 investor meetings.
Live webcasts will be available on their website.
Prothena Corporation plc (NASDAQ:PRTA) announced the appointment of Helen S. Kim to its Board of Directors. With over 27 years of experience in biotechnology, Ms. Kim previously served as Executive Vice President at Kite Pharma, leading to its acquisition by Gilead. Her extensive background is expected to guide Prothena's robust pipeline as the company approaches commercialization. Following this appointment, the Board will expand to 10 directors. Ms. Kim expressed enthusiasm about contributing to Prothena's advancement in treating neurodegenerative and rare diseases.
Prothena Corporation reported a net loss of $41.2 million for Q2 2022, compared to a net income of $27.6 million in Q2 2021. Total revenue decreased to $1.3 million, down from $60.1 million year-over-year. Cash position remains strong at $510.1 million, with a projected net cash usage of $120 to $132 million for 2022. The pipeline includes promising therapies for Alzheimer’s, with FDA Fast Track designation for PRX012, and topline data expected from PRX005 by year-end. The company maintains a focus on advancing multiple clinical programs.
Dublin-based Prothena Corporation plc (NASDAQ:PRTA) announced the granting of a stock option to a new employee, allowing the purchase of 35,000 ordinary shares at an exercise price of $29.70 per share, equivalent to the closing price on August 1, 2022. The option will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter. This grant is part of the Company’s 2020 Employment Inducement Incentive Plan aimed at attracting new talent.
Prothena Corporation plc (NASDAQ:PRTA) will release its second quarter and first six months of 2022 financial results on August 8, 2022, after U.S. market close. The company will not hold a conference call to discuss these results, adhering to past practices. Prothena specializes in developing therapeutics targeting neurodegenerative diseases and amyloid disorders, leveraging extensive research expertise. Their pipeline includes treatments for conditions such as AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, and Parkinson's disease.
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology firm, announced the hiring of two employees, accompanied by a grant of options to purchase 50,000 ordinary shares. The exercise price is set at $27.89, aligning with the closing price on July 1, 2022. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly. This grant is part of the 2020 Employment Inducement Incentive Plan.
Prothena specializes in therapeutics for neurodegenerative diseases and amyloid disorders.
Prothena Corporation plc (NASDAQ:PRTA) announced that its senior management will participate in a fireside chat at the Jefferies Healthcare Conference on June 8, 2022, at 8:30 AM ET. The event will be accessible via a live webcast on the company's investor relations website, with a replay available for 90 days afterward. Prothena focuses on developing therapeutics for neurodegenerative and rare peripheral amyloid diseases, leveraging its expertise in protein dysregulation. The company is advancing a robust pipeline targeting conditions like AL amyloidosis and Alzheimer's disease.
Prothena Corporation reported a net loss of $36.3 million for Q1 2022, showing a slight improvement from $36.7 million the previous year. Total revenue climbed to $1.2 million, primarily driven by collaboration revenue from Bristol Myers Squibb. Operating cash usage was $37.4 million, with cash reserves standing at $544.3 million. Prothena's pipeline includes the Alzheimer's treatment PRX012, which has received FDA Fast Track designation and is currently in Phase 1 trials. The company expects to end 2022 with around $454 million in cash, despite projected net losses of up to $170 million.
Prothena Corporation plc (NASDAQ:PRTA) will announce its first quarter 2022 financial results on May 5, 2022, after U.S. market close. The company specializes in investigational therapeutics targeting protein dysregulation, focusing on neurodegenerative and rare peripheral amyloid diseases. Prothena has a diverse pipeline aimed at treating conditions such as AL amyloidosis, ATTR amyloidosis, Alzheimer's, and Parkinson's diseases. Notably, there will be no conference call accompanying the results release.
Prothena Corporation plc (NASDAQ: PRTA) announced FDA Fast Track designation for its investigational anti-amyloid beta therapy, PRX012, aimed at treating Alzheimer’s disease. This designation facilitates accelerated development for drugs addressing serious conditions. PRX012, currently in Phase 1 studies, shows promise with high binding strength and effective delivery methods. With approximately 50 million people affected globally by Alzheimer’s, this therapy addresses a significant unmet medical need.